Perrigo rejects Mylan’s unsolicited exchange offer as inadequate
Perrigo said that its Board of Directors has reviewed Mylan’s unsolicited tender offer to acquire all of the outstanding shares of Perrigo and, in consultation with its financial
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.